We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

94 hedge funds and large institutions have $140M invested in Y-mAbs Therapeutics in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $107M → $140M (+$32.4M)

16% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 32

1.88% more ownership

Funds ownership: 45.07% → 46.95% (+1.9%)

6% more call options, than puts

Call options by funds: $17K | Put options by funds: $16K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 98 → 94 (-4)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

Holders
94
Holders Change
-4
Holders Change %
-4.08%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
11
Increased
37
Reduced
32
Closed
14
Calls
$17K
Puts
$16K
Net Calls
+$1K
Net Calls Change
-$15K

Top Buyers

Rank Fund Capital Flow
1
CP
Caligan Partners
New York
+$5.93M
2
BFM
Boothbay Fund Management
New York
+$3.92M
3
BlackRock
BlackRock
New York
+$2.57M
4
Morgan Stanley
Morgan Stanley
New York
+$2.21M
5
CCIA
Campbell & Co Investment Adviser
Maryland
+$477K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.88M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.61M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.6M
4
AQR Capital Management
AQR Capital Management
Connecticut
-$1.34M
5
Prudential Financial
Prudential Financial
New Jersey
-$996K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$19.9M +$2.57M +443,724 +18%
Vanguard Group
2
Vanguard Group
Pennsylvania
$15.3M +$71.3K +12,330 +0.6%
SI
3
Sofinnova Investments
California
$15M – – –
PCH
4
Polar Capital Holdings
United Kingdom
$14M -$269K -46,426 -2%
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$9.03M -$147K -25,430 -2%
CP
6
Caligan Partners
New York
$7.15M +$5.93M +1,025,104 +4,396%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$5.47M -$51.4K -8,880 -1%
State Street
8
State Street
Massachusetts
$5.19M +$118K +20,434 +3%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$5.04M +$160K +27,715 +4%
BFM
10
Boothbay Fund Management
New York
$4.73M +$3.92M +678,548 +4,365%
Morgan Stanley
11
Morgan Stanley
New York
$3.34M +$2.21M +382,416 +355%
N
12
Nuveen
North Carolina
$2.73M +$240K +41,541 +12%
Goldman Sachs
13
Goldman Sachs
New York
$2.71M +$49.8K +8,604 +2%
Los Angeles Capital Management
14
Los Angeles Capital Management
California
$2.43M +$304K +52,610 +17%
Northern Trust
15
Northern Trust
Illinois
$2.22M +$13K +2,252 +0.7%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$2.14M +$414K +71,512 +30%
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$1.72M -$1.61M -277,519 -52%
Charles Schwab
18
Charles Schwab
California
$1.69M -$11.2K -1,938 -0.8%
Renaissance Technologies
19
Renaissance Technologies
New York
$1.19M -$360K -62,290 -26%
Connor, Clark & Lunn Investment Management (CC&L)
20
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.16M -$80.7K -13,945 -8%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$1.13M -$215K -37,200 -18%
SCM
22
Soleus Capital Management
Connecticut
$1.07M – – –
Citadel Advisors
23
Citadel Advisors
Florida
$938K -$1.6M -276,807 -67%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$818K +$2.09K +362 +0.3%
Marshall Wace
25
Marshall Wace
United Kingdom
$783K +$91.7K +15,855 +16%
1
2 3 4 5

YMAB Hedge Fund Activity: Q4 2023 in Review

94 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2023, worth a combined $140M — up 30% from $107M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of YMAB and 11 opened new positions — a net loss of 3 holders — while 32 trimmed existing stakes and 37 added.

The largest buyer was Caligan Partners, adding an estimated $5.93M. The largest seller was Millennium Management, cutting an estimated $1.88M.

  • 94 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2023, down from 98 in Q3 2023.
  • Funds reported $140M of Y-mAbs Therapeutics stock for Q4 2023, up 30% quarter-over-quarter.
  • 11 funds opened new Y-mAbs Therapeutics positions in Q4 2023 and 14 closed out, a net change of -3 holders.
  • The largest Y-mAbs Therapeutics buyer in Q4 2023 was Caligan Partners, an estimated $5.93M added.
  • The largest Y-mAbs Therapeutics seller in Q4 2023 was Millennium Management, an estimated $1.88M sold.

Based on aggregated 13F filings for Q4 2023.